about
Lauric acid-rich medium-chain triglycerides can substitute for other oils in cooking applications and may have limited pathogenicityPentoxifylline for vascular health: a brief review of the literatureCoenzyme Q10 for the treatment of heart failure: a review of the literaturePractical strategies for targeting NF-kappaB and NADPH oxidase may improve survival during lethal influenza epidemics.Supplemental creatine may decrease serum homocysteine and abolish the homocysteine 'gender gap' by suppressing endogenous creatine synthesis.Suppression of dolichol synthesis with isoprenoids and statins may potentiate the cancer-retardant efficacy of IGF-I down-regulation.Vegan proteins may reduce risk of cancer, obesity, and cardiovascular disease by promoting increased glucagon activity.The therapeutic potential of glucose tolerance factor.Prospects for nutritional control of hypertension.β-Alanine and orotate as supplements for cardiac protectionComplementary vascular-protective actions of magnesium and taurine: a rationale for magnesium taurate.Magnesium taurate for the prevention and treatment of pre-eclampsia/eclampsia.Magnesium taurate and fish oil for prevention of migraine.Acarbose, lente carbohydrate, and prebiotics promote metabolic health and longevity by stimulating intestinal production of GLP-1.The "rejuvenatory" impact of lipoic acid on mitochondrial function in aging rats may reflect induction and activation of PPAR-gamma coactivator-1alpha.Interleukin-1beta may act on hepatocytes to boost plasma homocysteine - The increased cardiovascular risk associated with elevated homocysteine may be mediated by this cytokine.Capsaicin may have important potential for promoting vascular and metabolic health.Red Yeast Rice Plus Berberine: Practical Strategy for Promoting Vascular and Metabolic Health.Synergistic denaturant therapy--a general strategy for treatment of solid malignancies.DL-phenylalanine markedly potentiates opiate analgesia - an example of nutrient/pharmaceutical up-regulation of the endogenous analgesia system.Sulfated glycosaminoglycans and glucosamine may synergize in promoting synovial hyaluronic acid synthesis.Enhanced synovial production of hyaluronic acid may explain rapid clinical response to high-dose glucosamine in osteoarthritis.Cytostatic and reverse-transforming therapies of cancer - a brief review and future prospects.Rationale for a novel immunotherapy of cancer with allogeneic lymphocyte infusion.Plant-based diets relatively low in bioavailable phosphate and calcium may aid prevention and control of prostate cancer by lessening production of fibroblast growth factor 23.Homologous physiological effects of nutritional antioxidants and eicosapentaenoic acid.A general strategy for the use of allogeneic lymphocyte infusions in the treatment of disorders characterized by impaired helper or suppressor T cell function: autoimmune diseases and the acquired immunodeficiency syndrome (AIDS).Cimetidine as an adjuvant for allogeneic lymphocyte immunotherapy of cancer.An antithrombotic role for nutritional antioxidants: implications for tumor metastasis and other pathologies.The unique merits of a low-fat diet for weight control.Integration of allogeneic lymphocyte immunotherapy with short-course chemotherapy and hypoenergic hyperthermia: a "triple-threat" treatment for disseminated cancer.An expanded concept of "insurance" supplementation--broad-spectrum protection from cardiovascular disease.Maturity-onset diabetes mellitus--toward a physiological appropriate management.Rationales for micronutrient supplementation in diabetes.Hormonal and nutritional enhancement of Na+-K+-ATPase activity may aid the prevention and treatment of essential hypertension.Nutritional modulation of mineralocorticoid and prostaglandin production: potential role in prevention and treatment of gastric pathology.Management of acute myocardial infarction with natural physiological agents.A practical prescription for cancer prevention--synergistic use of chemopreventive agents.Toward a "bio-energy supplement" -- a prototype for functional orthomolecular supplementation.Non-toxic inhibition of extracellular tumor enzymes--potential in cancer therapy.
P50
Q26740087-9A3B389A-CA53-4D08-A04E-37418A2393C1Q26766371-7CBAEF43-6AA8-484D-B25D-DDAF8D855AE4Q26778097-6FFAB4C0-E545-4AA0-94E1-4B55516D3F63Q30378621-6D806172-BF4A-4387-A849-398FBD337BC0Q31763979-2EA8AD6F-648B-46A4-9956-B9949594FDAEQ31764932-EC79818E-FFA1-42C6-8E0C-E6894982BA81Q33891191-490FD716-2948-4978-ACFA-43EFCD753693Q34275534-63538553-1750-432E-B1A0-C41A3593453BQ34281899-D6C63061-A524-4B3F-846A-BBA4A4679F2FQ34304463-91BFD722-D8BC-4D55-A376-E7234447B107Q34387479-D3FD7766-66C2-4734-99D3-DBC35D379599Q34406881-6D97B512-2486-4259-AADA-C455D4D22239Q34410787-78384767-5D66-4B14-B49B-862FF1F0FCDDQ35047406-0C2AB082-7A83-41F1-834C-26F73D4C9DEFQ37267815-26B453EE-794D-42A4-88EB-EA257DA2381AQ38431413-475B8F9D-C509-4520-9A4D-54815388AE82Q38538371-ADAED1B6-6CC1-4DE5-B564-70F73C94AF4CQ38574218-1537CDD0-5DE1-44EF-88FD-3E4E58CE0176Q38579316-F07FC00E-27E2-4EEE-AB7D-5E98094BF144Q39426524-ACAAE415-78CA-43DE-BFDC-13D44E69C9EFQ39429209-E6443914-7EB9-4486-A398-39CD580488A9Q39445489-1BD1D571-1EBB-4E42-B52C-E884D637982BQ40104082-D72BF8D8-1385-48A1-84A8-3435BA21BD57Q40199452-90F7A9C6-A9CB-42DC-9802-787E8CF3A4CDQ40369546-E9E48011-6F32-46E0-BE69-7983CF691899Q41370379-4EFE57FC-1206-4845-934A-A78627EB14A7Q41394051-11D8FF0F-0A2D-4DE0-BB6A-00D541BD8D90Q41394884-EE1BDFBF-6F32-4467-9FF0-F6197666399AQ41450436-AF75EC8C-F941-4D9A-8521-0D4972C33C2DQ41462403-B2FA1A96-F16D-4E01-BFD5-DD1637B0E768Q41498868-7DA3DF1A-6419-488F-B6D2-2BF1B97F06E5Q41540608-6E4B0764-BE59-423E-A8ED-6276BA1B7EABQ41551711-ABA149C0-28B1-4C7E-B1DC-C4FF87367467Q41560235-D5FD49B3-97AB-432A-A2CF-95E0690B4C82Q41560704-763350DB-E012-46E7-821D-BA8529A24115Q41563471-FCBF3AE6-456E-467D-94D4-FECBF3F17DA0Q41570960-376BFDEC-A430-40A3-A47A-3B215767CB74Q41576369-5656179E-96B7-4374-9C0B-1682ED0FD834Q41601120-81804881-DAC6-42C4-B28C-B1714BB3C721Q41601928-3179C087-D6CF-4AA4-98BA-B43C6A2D39F9
P50
name
Mark Frederick McCarty
@ast
Mark Frederick McCarty
@en
Mark Frederick McCarty
@nl
type
label
Mark Frederick McCarty
@ast
Mark Frederick McCarty
@en
Mark Frederick McCarty
@nl
altLabel
M F McCarty
@en
M McCarty
@en
M. F. McCarty
@en
M. McCarty
@en
Mark F McCarty
@en
Mark F. McCarty
@en
Mark McCarty
@en
McCarty M
@en
McCarty M. F.
@en
McCarty M.
@en
prefLabel
Mark Frederick McCarty
@ast
Mark Frederick McCarty
@en
Mark Frederick McCarty
@nl